Avant Bio Fund II LP
Open: first sale May 2023, per Form D (fund age approximates vintage)
- Vintage
- 2023
- Fund size
- $57.45M (Form D)
- Stages
- Not stated
- Sectors
- Healthtech
- Regions
- Not stated
01 · Thesis
Avant Bio invests in innovative life sciences and healthtech companies developing Therapeutic Enabling Technologies, including biomanufacturing tools and automation, machine learning and AI applications, healthtech, techbio, and contract services, to make therapies more accessible.Inferred from the firm's website
02 · Initial check
$575K to $958K (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Daniella Kranjac, Founding General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideAVANT BIO is dedicated to fueling innovative companies in the Life Sciences and Healthtech space that are developing Therapeutic-Enabling Technologies capable of making therapies more accessible and unlocking new possibilities.
AVANT BIO is dedicated to fueling innovative companies in the Life Sciences and Healthtech space that are developing Therapeutic-Enabling Technologies capable of making therapies more accessible and unlocking new possibilities.
https://avant.bio/our-approach/
06 · Sources
Last verified: Oct 28, 2026